Dedicated to discovering, developing, and commercializing novel therapeutics to transform the treatment of patients with grievous blood-based disorders


Global Blood Therapeutics, Inc. (NASDAQ: GBT) is a clinical-stage biopharmaceutical company dedicated to discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders with significant unmet need. GBT is developing its lead product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease. GBT is also investigating GBT440 for the treatment of hypoxemic pulmonary disorders in two ongoing Phase 2a studies in patients with idiopathic pulmonary fibrosis.


Year Invested: 2012
Location: South San Francisco, Calif.
Visit: www.globalbloodtx.com

Recent News

June 6, 2017
Global Blood Therapeutics Announces Participation at the Goldman Sachs 38th Annual Global Healthcare Conference

May 18, 2017
Global Blood Therapeutics Announces Upcoming Presentation of GBT440 Data in Adolescents with Sickle Cell Disease at European Hematology Association’s 22nd Congress

May 1, 2017
Global Blood Therapeutics Reports Recent Business Progress and Provides First Quarter 2017 Financial Results

Read More News

Associated Team Members

Kevin Starr
Partner

Mark A. Goldsmith, M.D., Ph.D.
Venture Partner

Craig Muir
Partner/Chief Technology Officer

Charles Homcy, M.D.
Partner

Glenn Pierce, M.D., Ph.D.
ENTREPRENUER-IN-RESIDENCE